An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- New test may soon detect curable hypertensionon September 6, 2019 at 2:58 pm
Patients here with hypertension may soon have access to a scan to test if they have a curable form of the disease. The scan is expected to be less invasive, and could be more accurate, than current ...
- HOPE 4: Hypertension Screening in Community Reduces CV Riskon September 6, 2019 at 11:37 am
PARIS — A community-based initiative, in which nonphysician healthcare workers screened individuals for hypertension in their own homes and community centers in two middle-income countries, resulted ...
- Tivus Ultrasound System for Pulmonary Arterial Hypertension Gets FDA Breakthrough Designationon September 6, 2019 at 10:03 am
SoniVie, a company based in Israel, won FDA Breakthrough Device Designation for its TIVUS intravascular ultrasound system for patients suffering from pulmonary arterial hypertension (PAH). Currently ...
- New imaging technique to diagnose hypertension | Videoon September 6, 2019 at 8:06 am
Researchers in Singapore have come up with a non-invasive imaging technique that can identify patients who suffer from hypertension. It is the first of its kind in Asia, and is undergoing clinical ...
- SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System in the Treatment of Pulmonary Arterial Hypertension (PAH)on September 6, 2019 at 4:30 am
TEL AVIV, Israel, Sept. 6, 2019 /PRNewswire-PRWeb/ -- SoniVie, an Israeli company developing a novel system for the treatment of PAH, today announced that it has been granted Breakthrough Device ...
- Patients may soon have access to new scan to identify those with curable hypertensionon September 6, 2019 at 4:09 am
SINGAPORE - While some patients with hypertension in the past have had to endure an invasive and difficult procedure to assess if they have a curable form of the disease, a new non-invasive procedure ...
- Best strategy for managing hypertension and preeclampsia at end of pregnancyon September 5, 2019 at 12:27 am
In 2009, the Hypertension and Preeclampsia Intervention Trial At near Term-I (HYPITAT- I) trial showed that inducing labor in women with gestational hypertension or preeclampsia at the end of ...
- The hidden dangers of 'white coat hypertension'on September 3, 2019 at 4:19 pm
NEW YORK (CNN) A study shows 30 percent of patients with higher than normal blood pressure readings experience "white coat hypertension," a phenomenon where blood pressure spikes in a clinical setting ...
- Salt Substitute Shakes Up Hypertension in Community Trialon September 3, 2019 at 9:04 am
PARIS -- A community-wide salt substitution intervention improved blood pressure and hypertension control levels, a pragmatic trial from Peru showed. Providing all families, shops, bakeries, and ...
via Bing News